Franklin Genomic AdvancementHELXETF
13F holders, Q1 2026 (March 31)6holders
2new positions
2sold out
1famous investor
$33.05avg. 13F price*
At the end of Q1 2026, 6 institutions reported holding Franklin Genomic Advancement (HELX) in their 13F filings, unchanged from Q4 2025. 2 opened new positions and 2 sold out. The largest holders were Citadel Advisors ($1.2M), LPL Financial LLC ($222K) and Franklin Resources Inc. ($88K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Franklin Genomic Advancement
- CUSIP
- 35473P520
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $1.3M |
| Exits | 2 | $39K |
All 13F filers, Q4 2025 → Q1 2026: 40,426 shares bought and 6,291 shares sold, net +34,135 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Citadel Advisors | 0.00% | New | 37,568 | $1.2M |
| LPL Financial LLC | 0.00% | Reduce -39.8% | 6,706 | $222K |
| Franklin Resources Inc. | 0.00% | New | 2,675 | $88K |
| Osaic Holdings, Inc. | 0.00% | Reduce -25.4% | 2,338 | $77K |
| Harbour Investments, Inc. | 0.00% | Add +9.1% | 1,650 | $55K |
| UBS Group AG | 0.00% | Add +102.3% | 89 | $3K |
"% of holder's portfolio" is HELX's weight in each manager's 13F, not the share of Franklin Genomic Advancement the manager owns.